Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PRKCI | P41743 | 9/20 | 0.54 |
| ▸ | PDE5A | O76074 | 4/20 | 0.53 |
| ▸ | GBA1 | P04062 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113677 | 0.89 | PDE5A (0.62) | KDM4EMAPK1PRKCIPDE5AGBA1 | |
| SCHEMBL5121366 | 0.88 | GBA1 (0.66) | KDM4EMAPK1PDE5AGBA1PTGS1 | |
| SCHEMBL5120106 | 0.87 | PRKCI (0.73) | KDM4EMAPK1PRKCIPDE5AGBA1 | |
| SCHEMBL5117543 | 0.87 | KDM4E (0.64) | KDM4EMAPK1PRKCIPDE5AGBA1 | |
| SCHEMBL8169995 | 0.86 | PDE5A (0.50) | KDM4EMAPK1PRKCIPDE5ASLC6A3 | |
| SCHEMBL5123744 | 0.84 | KDM4E (0.60) | KDM4EMAPK1PRKCIPDE5AGBA1 | |
| SCHEMBL5125720 | 0.83 | METAP1 (0.65) | KDM4EMAPK1PDE5AGBA1ADORA2A | |
| SCHEMBL8184676 | 0.83 | PDE5A (0.47) | KDM4EMAPK1PDE5ASLC6A3 | |
| SCHEMBL5118039 | 0.83 | ADORA2A (0.51) | KDM4EMAPK1PDE5AGBA1ADORA2A | |
| SCHEMBL31045059 | 0.83 | FLT3 (0.49) | KDM4EMAPK1PRKCIPDE5AGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | KDM4E 257/4885MAPK1 899/4885PRKCI 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.